Kornimate/medical-research-clean huggingface dataset:
tailored communication to reduce cardiovascular risk

Conditions: Hypercholesterolemia; Coronary Artery Disease; Dyslipidemia; Hypertension

Summary: the primary goal of the trial is to test the feasibility and efficacy of a cardiovascular disease quality improvement system that couples emr-based patient identification with individually tailored patient messages. the study will test the hypothesis that that a tailored patient-directed approach to cardiovascular risk reduction integrated into patients' primary care delivery site will improve control of elevated low-density lipoprotein cholesterol and other card iac risk factors more than routine care alone for patients at intermediate or high risk for cardiovascular disease.


Eligibility criteria:
inclusion criteria: * age 40 to 79 years * medication list does not include an active lipid lowering medication * the patient does not have a diagnosis in the past medical history, active problem list or past visit encounter of coronary heart disease, heart failure, stroke, diabetes mellitus, or peripheral arterial disease * the patient has an enrolled study physician recorded as his/her primary care physician * the patient has an ldl cholesterol that meets one or more of the criteria listed below. ldl cholesterol \>= 130 mg/dl and estimated framingham risk score 10-20% ldl cholesterol \>= 100 mg/dl and estimated framingham risk score \>20% ldl cholesterol \>= 160 mg/dl and estimated framingham risk score 5% to \<10%. exclusion criteria: * age \ 79 years * medication list includes an active lipid lowering medication * the patient hase a diagnosis in the past medical history, active problem list or past visit encounter of coronary heart disease, heart failure, stroke, diabetes mellitus, or peripheral arterial disease * the patient does not have an enrolled study physician recorded as his/her primary care physician * the patient does not have an ldl cholesterol that meets one or more of the criteria listed below. ldl cholesterol \>= 130 mg/dl and estimated framingham risk score 10-20% ldl cholesterol \>= 100 mg/dl and estimated framingham risk score \>20% ldl cholesterol \>= 160 mg/dl and estimated framingham risk score 5% to \<10%.

Keywords: health education health knowledge, attitudes, practice hypolipidemic agents/therapeutic use patient education as topic
zr-mtx for piol phase ii trial

Conditions: Primary Intraocular Lymphoma

Summary: this is a prospective single-arm phase ii study, with the purpose of evaluating the efficiency of zr-mtx regimen (rituximab, zanubrutinib and methotrexate) combined with intravitreal methotrexate, then followed by minimal residual disease directed zanubrutinib maintenance in newly-diagnosed primary intraocular lymphoma. the primary endpoint of this study is progression-free survival (pfs).

all the patients will be treated with zr regimen (rituximab 375mg/m2 iv d1, zanubrutinib 160mg bid, 21 days per cycle) as induction regimen. the response will be evaluated after 2 cycles of zr regimen. patients who achieved complete remission (cr) or partial remission (pr) or stable disease (sd) will receive 2 more cycles of zr regimen. the patients with progressed disease (pd) will withdraw from the trial and receive salvage regimens. then 2 more cycle of zr regimen will be administrated. patients will be evaluated again, those achieved cr or pr or sd will continue to receive 2 cycles of zr-mtx regimen (rituximab 375mg/m2 iv d1, methotrexate 3.5g/m2 iv d1, zanubrutinib 160mg bid, 21 days per cycle), while those pd will drop out. in the meantime, intravitreal methotrexate will be given at a dose of 400ug for 16 doses. after total 6 induction cycles, the investigators evaluate the efficiency again, the patients with cr and mrd negativity (by csf il-10 and cfdna) will stop treatment. those with mrd positive cr or pr or sd will go to zanubrutinib maintenance for 2 years or until progression of the disease (pd), unacceptable toxicity, or patient/investigator discretion. and the patients with pd will receive a salvage regimen. during following-up, surveillance ophthalmologic examination, and brain magnetic resonance imaging (mri) scans can be performed every 3 months up to the first 2 years, followed by the doctor's visit every 6 months for up to 5 years or disease relapses.

Eligibility criteria:
inclusion criteria: * • newly-diagnosed primary vitreoretinal lymphoma * ecog≤2 * creatinine clearance rate (ccr) ≥ 60ml/h, according to cockcroft-gault * total bilirubin # 2 upper limits of normal, alanine aminotransferase#alt# \< 3 upper limits of normal * sign the informed consent * women of childbearing potential must understand that the study medication could have a potential teratogenic risk. they should undergo complete contraception during the study period. * male subjects must agree to use condoms throughout study drug therapy. exclusion criteria: * • primary central nervous system lymphoma involved eyes and brain * systemic b cell lymphoma involved eyes * pre-existing uncontrolled active infection * clinical evidence of grade 3 or 4 heart failure as defined by the new york heart association criteria * pregnancy or active lactation * co-existing tumors * hiv or hbv or hcv infection

Keywords: primary intraocular lymphoma
study of genes and environment in patients with breast cancer in the east anglia region of the united kingdom

Conditions: Breast Cancer

Summary: rationale: studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this study is looking at genetic susceptibility to cancer and interactions between genes and the environment in patients with breast cancer.

objectives: * to obtain epidemiological information and biological material on a population-based series of breast cancer cases. * to establish whether polymorphisms in putative cancer predisposition genes are associated with an increased risk of breast cancer by comparing the frequency of alterations in breast cancer patients with the corresponding frequency in controls. * to define the proportion of breast cancer incidence attributable to mutations in such genes. * to examine the interactions between genetic and nongenetic risk factors. * to evaluate the relationship between pathological and clinical characteristics of breast cancers and germline genotype. outline: this is a multicenter study. patients complete an epidemiological questionnaire that covers standard known breast cancer risk factors including reproductive history, oral contraceptive use, hormone replacement therapy use, family history, and alcohol consumption. the questionnaire will also request identifying information on the patient's first-degree relatives. blood samples are collected from patients. dna is extracted from these blood samples, from samples collected from cancer-free control participants in mrec-search-control, and from additional controls through the european prospective investigation of cancer (epic) study (a population-based study of diet and health based in norfolk, east anglia). dna samples are analyzed for polymorphisms of low penetrance cancer susceptibility genes. in addition to the breast cancer patients recruited for this study, patients with malignant melanoma and lymphoma, colorectal, ovarian, prostate, colorectal, bladder, kidney, pancreatic, and esophageal cancer, and brain tumors are recruited for the following related clinical trials: mrec-search-colorectal, mrec-search-ovarian, mrec-search-prostate, mrec-search-endometrial, and mrec-search-cancer.

Eligibility criteria:
disease characteristics: * diagnosis of breast cancer within the past 5 years * identified through the east anglian cancer registry in the east anglia region of the united kingdom * hormone receptor status not specified patient characteristics: * menopausal status not specified * identified by the patient's general practitioner as fit to contact for this study * no serious mental illness or retardation prior concurrent therapy: * not specified

Keywords: breast cancer male breast cancer
prospective pilot study validating the canadian c-spine rule pre-hospital

Conditions: Injury of Cervical Spine; Cervical Spine Fractures

Summary: this study is designed to evaluate the safety, level of performance and level of comfort with the canadian c-spine rule in a prehospital setting by emergency medicine undergraduates.


Eligibility criteria:
inclusion criteria: * alert, stable, adult patients presenting with an acute possible injury to the cervical spine * alert: gcs ≥ 14 * stable: * systolic blood pressure ≥ 90 mmhg * respiratory frequency 12 - 20 / min * adult ≥ 18 years old * acute: ≤ 4 * possible injury to the cervical spine: * posterior neck pain following any mechanism * no neck pain but visible injury above the clavicles * no neck pain or visible injury above the clavicles but a mechanism that indicates a cervical spine injury exclusion criteria: * acute paralysis (quadriplegia, paraplegia) * penetrating trauma to the neck * patients with known vertebral disease (ankylosing spondylitis, rheumatoid arthritis, spinal stenosis, or previous cervical spine surgery) * pregnancy

Keywords: canadian c-spine rule prehospital emergency care cervical spine injuries cervical spine fractures emergency medicine undergraduates
a comparison of oxycodone/naloxone and oxycodone after laparoscopic hysterectomy

Conditions: Postoperative Pain; Opioid Induced Constipation

Summary: objectives: primary objective: * to demonstrate that the treatment with oxn pr tablets up to 72 hrs after surgery is superior to the treatment with oxypr with regards to constipation in subjects with postoperative pain after laparoscopic hysterectomy based on interviews 24h, 72 h and 1 week postoperatively. the secondary objectives: * analgesic effect (including registration during the first 24 hrs) * to asses the frequency of pain rescue mediation use (in the double-blind phase, 0-72 hrs) * frequency of nausea and vomiting * frequency of other adverse events * appetite * mobilization the exploratory objectives: * overall patient satisfaction at 24, 72 hrs and 1 week


Eligibility criteria:
inclusion criteria: 1. females 18 -70 years 2. elective, non-malignant laparoscopic gynecological surgery in general anesthesia : hysterectomy/ myomectomy, asa 1, 2 and 3 3. subjects willing and able to participate the study and have provided informed consent form - exclusion criteria: 1. previous recent or regular opioid use (who step i pain treatment allowed) 2. any situation where opioids are contraindicated. 3. any history of moderate to severe hepatic impairment. 4. any history of severe respiratory depression with hypoxia and/or hypercapnia 5. any history of severe chronic obstructive pulmonary disease, cor pulmonal, acute severe bronchial asthma 6. subjects with evidence of non-opioid induced paralytic ileus 7. subjects with evidence of severely impaired pulmonary function, myxoedema, hypothyroidism 8. subjects with evidence of addison's disease (adrenal cortical insufficiency), toxic psychosis,cholelithiasis, prostate hypertrophy, alcoholism, delirium, pancreatitis, hypotension, hypertension, pre-existing cardiovascular diseases, head injury (due to the risk of increased intracranial pressure), epileptic disorder or predisposition to convulsions, or patients taking mao inhibitors. 9. any history of hypersensitivity to oxycodone / naloxone or to any of the excipients. 10. active alcohol or drug abuse and/or history of opioid abuse. 11. subjects with evidence of clinically unstable disease, as determined by medical history, clinical laboratory tests, ecg results, and physical examination that, in the investigator's opinion, preclude entry into the study. 12. subjects who have received an investigational medicinal product within 30 days of study entry (defined as the start of the screening period).
10% lidocaine spray for intrauterine device insertion

Conditions: Contraception; Intrauterine Device

Summary: intrauterine device (iud) insertion is a procedure that can cause pain. fear of pain during iud insertion is a barrier to use of this method. currently, there is no recommended standard method for reducing pain during this procedure. from cochrane database 2015, some lidocaine formulations, such as lidocaine spray, lidocaine gel and lidocaine paracervical injection, could reduce pain during iud insertion, but there is limited data on effect of lidocaine spray on reducing pain during insertion of iud.

intrauterine device (iud) is a high efficacy long-acting reversible contraceptive method. however, iud insertion is a procedure that require well-trained medical personnel and can cause pain in several steps during insertion such as applying tenaculum, applying uterine sound and insertion of iud. fear of pain during iud insertion is a barrier to use of this contraceptive method. previous researches reported mean pain score with using visual analog scale (vas) moderated pain (4.7/10 and 34.7-51.2/100). in several countries, pain control is used before iud insertion procedure. currently, there is no recommended standard method for reducing pain during this procedure. from cochrane database 2015, some lidocaine formulations, such as lidocaine spray, lidocaine gel and lidocaine paracervical injection, could reduce pain during iud insertion, but there is limited data on effect of lidocaine spray on reducing pain during insertion of iud. lidocaine is introduced to use for pain relieving in medical procedures with advantages of rapid action and minimal side effects.10% lidocaine spray is a form of local anesthetic method that use in obstetrics and gynecology procedures and has favorable efficacy in reducing pain. nevertheless, there were limited studies of 10% lidocaine spray during iud insertion. in this study, we investigate pain during iud insertion using lidocaine spray compared with placebo.

Eligibility criteria:
inclusion criteria: * woman who required for copper t iud insertion * body mass index 18.5 - 30 kg/m2 * communicable with thai language * new iud user exclusion criteria: * suspicion of pregnancy * puerperal sepsis/immediate post-septic abortion * untreated abnormal uterine bleeding * uterine anomaly/abnormal pathology distorting the uterine cavity * current pelvic inflammatory disease * untreated cervicitis/vaginitis * wilson's disease * copper allergy * known hypersensitivity to local anaesthetic * analgesic or anxiolytic use within the last 24 h before the procedure

Keywords: intrauterine device lidocaine spray
multicentric, transversal, descriptive, epidemiological study on the management of asthma in asthmatic middle east adult population

Conditions: Asthma

Summary: descriptive study on the management of asthma in asthmatic middle east adult population : algeria,egypt, irak,iran, jordan, koweit, lebanon, qatar,saudi,tunisia, uae

multicentric, transversal, descriptive, epidemiological study, conducted in a random sample of general practitioner and medical specialist (pulmonologist and/or allergologist) in the public and the private sector.

Eligibility criteria:
inclusion criteria: men and women, 18 years of age and older. asthmatic since at least one year before inclusion. patient's informed consent obtained. exclusion criteria: * patient concurrently participating to another study. patient with concomitant pulmonary disease. patient with psychiatric disorders. patient consulting for an asthma attack

Keywords: asthma control
application of newly developed endoscopic ultrasound with zone sonography technology for diagnosis of pancreatic caner

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to measure and compare the difference of sound speed between pancreatic cancer and non-pancreatic cancer, and determine the critical value of sound speed for benign and malignant pancreatic cancer. the sensitivity, specificity, accuracy, positive predictive value and negative predictive value for the diagnosis of pancreatic cancer are calculated, so as to evaluate the clinical application value of local sound speed measurement in the diagnosis of pancreatic cancer.

the investigators include patients who are found to have solid pancreatic mass on continuous imaging. all subjects are scanned by fuji film su-9000 ultrasonic system. after the lesions are found, local sound velocity measurement technology will be used to measure the sound velocity in the lesions. pathology diagnosis or clinical follow-up results will be regard as diagnostic gold standard to divide the patients into pancreatic cancer and pancreatic cancer group. the investigators will compare the sound velocity value if there is statistically significant difference between the two groups, build the receiver operating characteristic curve, calculation of pancreatic benign and malignant lesions of sound velocity threshold, and and the investigators will calculate the sensitivity, specificity, accuracy, positive predictive value and negative predictive value, to evaluate local sound velocity measurement in the diagnosis of pancreatic cancer clinical application value.

Eligibility criteria:
inclusion criteria: 1. patients aged between 18 and 75, gender is not limited. 2. evidence of solid pancreatic lesions have been found on imaging examination, including computed tomography, magnatic resonance imaging and endoscopic ultrasonography. 3. the lesion was greater 1cm. 4. the informed consent has been signed. exclusion criteria: 1. patients with serious cardiopulmonary diseases and poor general condition. 2. patients with other contraindications to endoscopic ultrasonography. 3. cannot or refuse to sign the informed consent.

Keywords: endoscopic ultrasound zone sonography technology
database for data collection in the context of an enhanced recovery after surgery program in oncology surgery

Conditions: Oncology

Summary: enhanced recovery after surgery programs (erp) includes multimodal approaches of perioperative patient's clinical pathways designed to achieve early recovery after surgery and a decreased length of hospital stay (los).

this database would also allow an objective evaluation of the quality of the surgical management and the follow-up. one of the evaluation criteria will be measured by the quantity and quality of publications from this database, and also by the increase in the activity of the service concerned.

Eligibility criteria:
inclusion criteria: * any patient operated including hysterectomy and or curettage, posterior pelvectomy, conventional laparoscopic or assisted robot, or laparotomy at the paoli-calmettes institute from 01 2016 to 12 2017, and incrementation from 2018. exclusion criteria: * non applicable.

Keywords: enhanced recovery after surgery program (erp)
comparison of the effects of face-to-face and internet-based bbat in fibromyalgia syndrome

Conditions: Fibromyalgia

Summary: the aim of our study is to compare the effects of face-to-face and internet-based bbat in patients diagnosed with fibromyalgia syndrome. h0: face-to-face and internet-based bbat have superiority over each other in patients diagnosed with fibromyalgia syndrome. h1: in patients diagnosed with fibromyalgia syndrome, face-to-face and internet-based bbat have no superiority over each other.

the aim of our study is to compare the effects of face-to-face and internet-based bbat in patients diagnosed with fibromyalgia syndrome. h0: face-to-face and internet-based bbat have superiority over each other in patients diagnosed with fibromyalgia syndrome. h1: in patients diagnosed with fibromyalgia syndrome, face-to-face and internet-based bbat have no superiority over each other. goals: 1. investigation of the effects of face-to-face and internet-based bbat on functional disability, pressure pain threshold, body awareness, posture, pain intensity, trunk position sense, postural control, balance, sleep quality, quality of life and inflammation level in patients diagnosed with fibromyalgia syndrome. 2. comparison of the effects of face-to-face and internet-based bbat on functional disability, pressure pain threshold, body awareness, posture, pain intensity, trunk position sense, postural control, balance, sleep quality, quality of life and inflammation level in patients diagnosed with fibromyalgia syndrome

Eligibility criteria:
inclusion criteria: 1. to be between the ages of 18-65 2. being diagnosed with fms according to acr 2016 criteria 3. to be diagnosed with fms at least 6 months before the study 4. reported pain intensity \> 4 (visual analog scale 0-10), 5. individuals that do not have barriers to basic body awareness therapy. exclusion criteria: 1. pregnancy or intention to become pregnant within the study period. 2. substance and alcohol abuse, major psychiatric disorder (preventing compliance), uncontrolled hypertension, diabetes, congestive heart failure, or other serious chronic medical condition that puts the patient at risk for the clinician to expose the patient to potentially serious consequences of their illness 3. those who have malignancy and those receiving chemotherapy and radiotherapy causing malignancy 4. those who have suffered from any musculoskeletal, neurological, rheumatological disorder or any condition that may interfere with evaluations (advanced respiratory or orthopedic problems such as fractures, sprains or strains, or spinal surgery) in the past 12 months -